Hikmah Zikriyani

Hikmah Zikriyani

Auto-generated profile, based on publicly available information

Hikmah Zikriyani


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
NANa’iLah I. Alifiyah
Na’iLah I. Alifiyah
WNWirdatun Nafisah
Wirdatun Nafisah
RRRizki Rizki
Rizki Rizki
AAArie Aryanto
Arie Aryanto
HZHikmah Zikriyani
Hikmah Zikriyani
Context: Breast cancer remains the most prevalent malignancy among women and presents therapeutic challenges due to adverse effects associated with conventional treatments. Cuminum cyminum seeds extract (CCSE), recognized for its antioxidant and antibacterial properties, has been investigated as a potential source of alternative therapeutic agents. Aims: To profile the phytochemical constituents of CCSE using GC-MS and to evaluate the predicted interactions of selected compounds with breast cancer–related proteins through in silico molecular docking analyses. Methods: The ethanolic extract of CCSE was analyzed by GC-MS, yielding the identification of 269 phytoconstituents. From these, three bioactive compounds—carvone, p-cymene, and linalool—were selected for further evaluation. Their potential anticancer activities were predicted using the PASS and CLC-Pred platforms, while drug-likeness properties were assessed through SwissADME. In silico toxicity profiles were also predicted using the ProTox-3.0 webserver. Pathway interactions were analyzed using the STITCH database. Molecular docking studies were then performed with AutoDock Vina in PyRx against Erα, MDM2, HER2, and caspase-3, with doxorubicin used as a reference drug. Results: The selected compounds were predicted to have potential anticancer activity against breast cancer through multiple mechanisms, including regulation of apoptosis. Carvone and p-cymene showed favorable predicted binding affinities for MDM2 and HER2 compared with doxorubicin, suggesting possible tumor-suppressive effects. Linalool was predicted to interact with MDM2, caspase-3, ERα, and HER2, with some affinities comparable to those of doxorubicin, indicating a potential role in modulating apoptosis pathways and receptor-mediated signaling. These findings provide preliminary in silico evidence of the breast cancer–related anticancer potential of CCSE bioactive compounds relative to doxorubicin, and further experimental validation is required. Conclusions: These findings suggest that CCSE-derived compounds may possess potential anticancer activity against breast cancer; however, further in vitro and in vivo validation is necessary.